Skip to main content Skip to footer content

We at tiakis develop novel and groundbreaking therapeutic solutions in indications with high unmet medical need. Based on the body’s own protective mechanisms and more than 20 years of clinical research.

“We are driven by the vision to improve human health.”

Learn more

Natural protection smart reinvented

Discover the gamechanger in the treatment of pulmonary-arterial hypertension and in the prevention of postoperative inflammatory complications: our investigational medical product Tiprelestat. Read now all you need to know about the pioneering anti-inflammatory and tissue protective drug being developed by tiakis BIOTECH AG.

Fully dedicated to a novel therapy approach

Read all about our goal to shift the paradigm toward a preventive and underlying cause focused approach for patients and why we believe in strong values like:


We want to improve the quality-of-life of patients suffering from chronic and acute pulmonary diseases such as pulmonary arterial hypertension or COVID-19. In addition, we seek to prevent postoperative inflammatory complications in patients undergoing highly invasive surgery.


We employ the human body’s own and natural defense mechanisms


More than 20 years of patient dedicated reliability towards our partners and stakeholders.

Located in Kiel. Connected around the world

Find out, why tiakis BIOTECH AG is the next generation preventive therapeutic biotech company and why we are developing our pioneering tissue protective drug Tiprelestat.